PFGT.F Stock Overview
A cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Pacific Edge Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.092 |
| 52 Week High | NZ$0.12 |
| 52 Week Low | NZ$0.044 |
| Beta | 1 |
| 11 Month Change | -5.60% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -38.70% |
| Change since IPO | -79.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| PFGT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how PFGT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PFGT.F performed against the US Market.
Price Volatility
| PFGT.F volatility | |
|---|---|
| PFGT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PFGT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PFGT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Peter Meintjes | www.pacificedgedx.com |
Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.
Pacific Edge Limited Fundamentals Summary
| PFGT.F fundamental statistics | |
|---|---|
| Market cap | US$66.27m |
| Earnings (TTM) | -US$17.22m |
| Revenue (TTM) | US$14.71m |
4.5x
P/S Ratio-3.9x
P/E RatioIs PFGT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFGT.F income statement (TTM) | |
|---|---|
| Revenue | NZ$25.23m |
| Cost of Revenue | NZ$11.75m |
| Gross Profit | NZ$13.48m |
| Other Expenses | NZ$43.01m |
| Earnings | -NZ$29.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 53.42% |
| Net Profit Margin | -117.07% |
| Debt/Equity Ratio | 0.5% |
How did PFGT.F perform over the long term?
See historical performance and comparison